Alpine Immune Financials
| ALPN Stock | USD 64.70 0.01 0.02% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.4 | 7.8617 |
|
|
The financial analysis of Alpine Immune is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for Alpine Immune includes many different criteria found on its balance sheet. For example, investors should never minimize Alpine Immune's ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor Alpine Immune's cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in Alpine Immune.
Net Income |
|
With this module, you can analyze Alpine financials for your investing period. You should be able to track the changes in Alpine Immune individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Alpine | Select Account or Indicator |
Understanding current and past Alpine Immune Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Alpine Immune's financial statements are interrelated, with each one affecting the others. For example, an increase in Alpine Immune's assets may result in an increase in income on the income statement.
The data published in Alpine Immune's official financial statements usually reflect Alpine Immune's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Alpine Immune Sciences. For example, before you start analyzing numbers published by Alpine accountants, it's critical to develop an understanding of what Alpine Immune's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Alpine Immune's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Alpine Immune's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Alpine Immune's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Alpine Immune Sciences. Please utilize our Beneish M Score to check the likelihood of Alpine Immune's management manipulating its earnings.
Alpine Immune Stock Summary
Alpine Immune competes with Terns Pharmaceuticals, Day One, Acumen Pharmaceuticals, Amylyx Pharmaceuticals, and MoonLake Immunotherapeuti. Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmuneinflammatory disorders, and other diseases. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington. Alpine Immune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 85 people.| Foreign Associate | Switzerland |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US02083G1004 |
| CUSIP | 02083G100 65481J109 |
| Location | Washington; U.S.A |
| Business Address | 188 East Blaine |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | NYSE Composite |
| Website | www.alpineimmunesciences.com |
| Phone | 206 788 4545 |
| Currency | USD - US Dollar |
You should never invest in Alpine Immune without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Alpine Stock, because this is throwing your money away. Analyzing the key information contained in Alpine Immune's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Alpine Immune Key Financial Ratios
Generally speaking, Alpine Immune's financial ratios allow both analysts and investors to convert raw data from Alpine Immune's financial statements into concise, actionable information that can be used to evaluate the performance of Alpine Immune over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Alpine Immune Sciences reports annually and quarterly.| Return On Equity | -0.13 | ||||
| Profit Margin | (0.55) % | ||||
| Operating Margin | 0.05 % |
Alpine Immune Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 54.1M | 144.1M | 255.9M | 286.7M | 381.8M | 400.9M | |
| Other Current Liab | 5.3M | 5.8M | 9.4M | 14.0M | 21.2M | 22.2M | |
| Net Debt | 233K | (12.4M) | (48.3M) | 845K | (34.0M) | (32.3M) | |
| Retained Earnings | (87.9M) | (115.9M) | (166.2M) | (224.0M) | (256.1M) | (243.3M) | |
| Accounts Payable | 1.5M | 582K | 3.3M | 4.3M | 3.6M | 2.0M | |
| Cash | 16.1M | 35.0M | 67.9M | 13.4M | 43.9M | 27.3M | |
| Other Current Assets | 1.8M | 1.5M | 4.7M | 3.0M | 1.9M | 1.7M | |
| Total Liab | 24.6M | 81.9M | 135.0M | 107.3M | 53.9M | 57.0M | |
| Total Current Assets | 42.3M | 107.1M | 192.0M | 241.0M | 330.0M | 346.5M | |
| Short Term Debt | 418K | 3.2M | 5.2M | 4.1M | 912K | 866.4K | |
| Common Stock | 19K | 24K | 30K | 46K | 60K | 63K | |
| Net Tangible Assets | 29.5M | 62.2M | 120.9M | 179.4M | 206.3M | 216.6M | |
| Other Assets | 254K | 35.2M | 5.0M | 409K | 1.0 | 0.95 | |
| Capital Surpluse | 117.4M | 177.9M | 287.3M | 404.5M | 465.1M | 488.4M | |
| Long Term Debt | 2.2M | 4.5M | 7.6M | 3.4M | 3.9M | 3.4M | |
| Short Long Term Debt | 418K | 2.5M | 4.6M | 3.4M | 3.9M | 2.2M | |
| Net Receivables | 686K | 388K | 25.3M | 709K | 749K | 711.6K | |
| Long Term Debt Total | 2.2M | 4.5M | 7.6M | 3.4M | 3.9M | 4.8M | |
| Net Invested Capital | 34.4M | 72.3M | 128.9M | 182.8M | 327.9M | 344.3M |
Alpine Immune Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what Alpine Immune's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 338K | 775K | 816K | 476K | 98K | 93.1K | |
| Operating Income | (43.6M) | (28.7M) | (49.9M) | (58.1M) | (44.3M) | (46.5M) | |
| Ebit | (43.6M) | (28.7M) | (49.9M) | (58.1M) | (44.3M) | (46.5M) | |
| Research Development | 35.8M | 27.2M | 58.7M | 70.2M | 80.3M | 84.3M | |
| Ebitda | (41.5M) | (27.2M) | (49.6M) | (55.0M) | (43.7M) | (45.9M) | |
| Income Before Tax | (41.9M) | (27.9M) | (50.4M) | (55.4M) | (32.1M) | (33.7M) | |
| Net Income | (42.5M) | (27.9M) | (50.3M) | (57.8M) | (32.2M) | (33.8M) | |
| Income Tax Expense | 682K | (6K) | (87K) | 2.3M | 103K | 97.9K | |
| Total Revenue | 1.7M | 9.3M | 23.4M | 30.1M | 58.9M | 61.8M | |
| Gross Profit | (34.1M) | (17.9M) | 22.8M | 29.5M | 58.3M | 61.2M | |
| Cost Of Revenue | 35.8M | 27.2M | 620K | 597K | 576K | 547.2K | |
| Interest Income | 1.2M | 245K | 259K | 3.3M | 10.0M | 10.5M | |
| Net Interest Income | 910K | (530K) | (557K) | 2.8M | 9.8M | 10.3M |
Alpine Immune Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Alpine Immune Sciences. It measures of how well Alpine is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Alpine Immune brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Alpine had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Alpine Immune has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 5.7M | 18.7M | 32.9M | (54.5M) | 30.5M | 32.1M | |
| Free Cash Flow | (36.2M) | 29.3M | (15.4M) | (44.2M) | (79.5M) | (75.5M) | |
| Depreciation | 468K | 578K | 620K | 597K | 576K | 384.5K | |
| Other Non Cash Items | 140K | 261K | 274K | (475K) | (8.0M) | (7.6M) | |
| Capital Expenditures | 821K | 802K | 118K | 412K | 487K | 382.6K | |
| Net Income | (41.9M) | (27.9M) | (50.3M) | (57.8M) | (32.2M) | (33.8M) | |
| End Period Cash Flow | 16.5M | 35.2M | 68.2M | 13.6M | 43.9M | 25.6M | |
| Investments | 17.6M | (72.8M) | (52.4M) | (112.9M) | (50.8M) | (53.3M) | |
| Change To Netincome | 3.2M | 4.5M | 7.2M | 9.8M | 11.3M | 11.8M |
Alpine Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Alpine Immune's current stock value. Our valuation model uses many indicators to compare Alpine Immune value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Alpine Immune competition to find correlations between indicators driving Alpine Immune's intrinsic value. More Info.Alpine Immune Sciences is rated second in return on equity category among related companies. It is rated second in return on asset category among related companies . At this time, Alpine Immune's Return On Equity is very stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Alpine Immune by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Alpine Immune's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Alpine Immune's earnings, one of the primary drivers of an investment's value.Alpine Immune Sciences Systematic Risk
Alpine Immune's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Alpine Immune volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourty with a total number of output elements of twenty-one. The Beta measures systematic risk based on how returns on Alpine Immune Sciences correlated with the market. If Beta is less than 0 Alpine Immune generally moves in the opposite direction as compared to the market. If Alpine Immune Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Alpine Immune Sciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Alpine Immune is generally in the same direction as the market. If Beta > 1 Alpine Immune moves generally in the same direction as, but more than the movement of the benchmark.
About Alpine Immune Financials
What exactly are Alpine Immune Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Alpine Immune's income statement, its balance sheet, and the statement of cash flows. Potential Alpine Immune investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Alpine Immune investors may use each financial statement separately, they are all related. The changes in Alpine Immune's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Alpine Immune's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Alpine Immune Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Alpine Immune is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Alpine has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Alpine Immune's financials are consistent with your investment objective using the following steps:- Review Alpine Immune's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Alpine Immune's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Alpine Immune's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Alpine Immune's stock is overvalued or undervalued.
Today, most investors in Alpine Immune Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Alpine Immune's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Alpine Immune growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Alpine Immune April 29, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Alpine Immune help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Alpine Immune Sciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Alpine Immune Sciences based on widely used predictive technical indicators. In general, we focus on analyzing Alpine Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Alpine Immune's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.98 | |||
| Information Ratio | 0.3042 | |||
| Maximum Drawdown | 36.97 | |||
| Value At Risk | (4.55) | |||
| Potential Upside | 15.55 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alpine Immune Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for Alpine Stock analysis
When running Alpine Immune's price analysis, check to measure Alpine Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alpine Immune is operating at the current time. Most of Alpine Immune's value examination focuses on studying past and present price action to predict the probability of Alpine Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alpine Immune's price. Additionally, you may evaluate how the addition of Alpine Immune to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |
Is Alpine Immune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alpine Immune. If investors know Alpine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alpine Immune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.64) | Revenue Per Share 1.178 | Quarterly Revenue Growth 10.114 | Return On Assets (0.08) | Return On Equity (0.13) |
The market value of Alpine Immune Sciences is measured differently than its book value, which is the value of Alpine that is recorded on the company's balance sheet. Investors also form their own opinion of Alpine Immune's value that differs from its market value or its book value, called intrinsic value, which is Alpine Immune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alpine Immune's market value can be influenced by many factors that don't directly affect Alpine Immune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alpine Immune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alpine Immune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alpine Immune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.